Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Reig

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Journal of Hepatology|January 27, 2019
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodulesZoe Mariño, Anna Darnell, Sabela Lens, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Gastroenterologia Y Hepatologia|April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guidelineRocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 15, 2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysisÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2025
Evolving epidemiology of HCC in SpainMargarita Sala, Sonia Pascual, Maria Rosa Rota Roca, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Journal of Hepatology|January 27, 2019
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodulesZoe Mariño, Anna Darnell, Sabela Lens, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Gastroenterologia Y Hepatologia|April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guidelineRocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 15, 2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysisÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2025
Evolving epidemiology of HCC in SpainMargarita Sala, Sonia Pascual, Maria Rosa Rota Roca, et al.
Pageof 7